Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 5/20 | 0.65 |
| ▸ | BRAF | P15056 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.49 |
| ▸ | TUBB | P07437 | 3/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.49 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.49 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.49 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466448 | 0.87 | RAF1 (0.67) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| SCHEMBL1466983 | 0.86 | RAF1 (0.86) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| SCHEMBL1466710 | 0.85 | RAF1 (0.66) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| SCHEMBL20525774 | 0.83 | RAF1 (0.86) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| SCHEMBL30951561 | 0.83 | LMNA (0.61) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| SCHEMBL15640909 | 0.83 | RAF1 (0.58) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| Mebendazole SCHEMBL3429179 | 0.83 | ABL1 (0.82) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| Mebendazole SCHEMBL15860 | 0.83 | ABL1 (0.82) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| Mebendazole SCHEMBL29409261 | 0.83 | ABL1 (0.82) | RAF1BRAFALDH1A1LMNACYP1A2 | |
| Mebendazole SCHEMBL21051200 | 0.82 | ABL1 (0.80) | RAF1BRAFALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885ALDH1A1 2799/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885ALDH1A1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.